BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18511242)

  • 1. Do we need another atypical antipsychotic?
    Kasper S
    Eur Neuropsychopharmacol; 2008 Aug; 18 Suppl 3():S146-52. PubMed ID: 18511242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The European Post-marketing Observational Serdolect (EPOS) Project: increasing our understanding of schizophrenia therapy.
    Wehnert A
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S27-30. PubMed ID: 9690967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sertindole: a review of clinical efficacy.
    Kane JM
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S59-63; discussion S63-4. PubMed ID: 9690972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sertindole, a new atypical antipsychotic for the treatment of schizophrenia.
    Brown LA; Levin GM
    Pharmacotherapy; 1998; 18(1):69-83. PubMed ID: 9469684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.
    Kane JM; Potkin SG; Daniel DG; Buckley PF
    J Clin Psychiatry; 2011 Feb; 72(2):194-204. PubMed ID: 20673553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
    Gallhofer B; Jaanson P; Mittoux A; Tanghøj P; Lis S; Krieger S
    Pharmacopsychiatry; 2007 Nov; 40(6):275-86. PubMed ID: 18030652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group.
    Daniel DG; Wozniak P; Mack RJ; McCarthy BG
    Psychopharmacol Bull; 1998; 34(1):61-9. PubMed ID: 9564200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug safety and efficacy evaluation of sertindole for schizophrenia.
    Karamatskos E; Lambert M; Mulert C; Naber D
    Expert Opin Drug Saf; 2012 Nov; 11(6):1047-62. PubMed ID: 22992213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety.
    Tamminga CA; Mack RJ; Granneman GR; Silber CJ; Kashkin KB
    Int Clin Psychopharmacol; 1997 Feb; 12 Suppl 1():S29-35. PubMed ID: 9179641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sertindole for the treatment of schizophrenia.
    Azorin JM; Kaladjian A; Fakra E; Adida M
    Expert Opin Pharmacother; 2010 Dec; 11(18):3053-64. PubMed ID: 21080854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-response relationship of sertindole and haloperidol using the pharmacopsychometric triangle.
    Bech P; Tanghøj P; Andreasson K; Overø KF
    Acta Psychiatr Scand; 2011 Feb; 123(2):154-61. PubMed ID: 20560900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis.
    Azorin JM; Murteira S; Hansen K; Toumi M
    BMC Psychiatry; 2008 Mar; 8():16. PubMed ID: 18366634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sertindole in schizophrenia: a clinical review.
    Zoccali RA; Bruno A; Muscatello MR
    J Clin Psychopharmacol; 2015 Jun; 35(3):286-95. PubMed ID: 25830594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sertindole causes distinct electrocardiographic T-wave morphology changes.
    Nielsen J; Graff C; Hardahl T; Andersen MP; Kristoffersen J; Struijk JJ; Toft E; Meyer JM
    Eur Neuropsychopharmacol; 2009 Oct; 19(10):702-7. PubMed ID: 19457646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology.
    Peuskens J; Tanghøj P; Mittoux A;
    Pharmacoepidemiol Drug Saf; 2008 May; 17(5):425-33. PubMed ID: 18384186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).
    Thomas SH; Drici MD; Hall GC; Crocq MA; Everitt B; Lader MH; Le Jeunne C; Naber D; Priori S; Sturkenboom M; Thibaut F; Peuskens J; Mittoux A; Tanghøj P; Toumi M; Moore ND; Mann RD
    Acta Psychiatr Scand; 2010 Nov; 122(5):345-55. PubMed ID: 20384598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of sertindole on QTD and TPTE.
    Nielsen J; Andersen MP; Graff C; Kanters JK; Hardahl T; Dybbro J; Struijk JJ; Meyer JM; Toft E
    Acta Psychiatr Scand; 2010 May; 121(5):385-8. PubMed ID: 20085555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sertindole in the long-term treatment of schizophrenia.
    Hale AS; Azorin JM; Lemming OM; Mæhlum E
    Int Clin Psychopharmacol; 2012 Jul; 27(4):231-7. PubMed ID: 22609816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment.
    Kasper S; Möller HJ; Hale A
    Eur Arch Psychiatry Clin Neurosci; 2010 Feb; 260(1):59-68. PubMed ID: 19455275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the efficacy, tolerability and safety of sertindole in clinical trials.
    Perquin L; Steinert T
    CNS Drugs; 2004; 18 Suppl 2():19-30; discussion 41-3. PubMed ID: 15461313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.